Shares of Scpharmaceuticals Inc (NASDAQ:SCPH) have been assigned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12-month consensus price objective of $12.67 for the company and are forecasting that the company will post ($0.45) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Scpharmaceuticals an industry rank of 75 out of 257 based on the ratings given to its competitors.
A number of equities analysts have recently commented on SCPH shares. Zacks Investment Research upgraded Scpharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a report on Friday, August 17th. ValuEngine cut Scpharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, November 12th.
Scpharmaceuticals (NASDAQ:SCPH) last released its quarterly earnings data on Tuesday, November 13th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.22. Equities analysts predict that Scpharmaceuticals will post -1.75 earnings per share for the current fiscal year.
Several institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System purchased a new position in shares of Scpharmaceuticals in the 1st quarter worth approximately $139,000. Northern Trust Corp boosted its holdings in shares of Scpharmaceuticals by 41.6% in the 2nd quarter. Northern Trust Corp now owns 67,932 shares of the company’s stock worth $384,000 after purchasing an additional 19,947 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Scpharmaceuticals by 1,268.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,664 shares of the company’s stock worth $133,000 after purchasing an additional 21,008 shares during the period. Colony Group LLC purchased a new position in shares of Scpharmaceuticals in the 2nd quarter worth approximately $131,000. Finally, Acadian Asset Management LLC purchased a new position in shares of Scpharmaceuticals in the 2nd quarter worth approximately $169,000. Hedge funds and other institutional investors own 44.17% of the company’s stock.
scPharmaceuticals Inc, a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting.
Featured Article: What is the yield curve?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.